Global Effort Needed to Combat Counterfeit Drugs: Report

A new report released by the Institute of Medicine (IOM) suggests that global efforts are needed to combat the manufacture and sale of low quality and fake drugs, which may pose serious risks for consumers. 

The IOM, in partnership with the FDA, assembled a committee of experts to gather information and address approaches in mitigating what the institute is identifying as a global issue.

The ad hoc committee addressed issues such as the trends, health effects, standards, identification, technology and collaboration surrounding the issue of substandard, falsified and counterfeit (SFC) medicines.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The IOM report was released on February 13, looking at issues involving SFC pharmaceuticals as a global trend, not just a national problem. It also focused on creating careful definitions for the terms substandard, falsified and counterfeit.

Of high importance within the report was also determining similarities and differences of the SFCs within different global regions. To that end, identifying factors which can be used to accurately determine pharmaceutical genuineness also plays a major role in combating SFC medicines.

Other items addressed in the report included a focus on weaknesses within the supply chain that allow SFCs to circulate, explaining the health effects to patients, determining global standards to help create stronger regulatory actions, processes that track, trace and authenticate genuine pharmaceuticals from the fake and how technology can help in the process of identifying and analyzing SFC medicines.

The IOM report also places a strong emphasis on collaboration and finding ways the government and industry as a whole can work together to fight the global problem of SFC drugs. The report outlines collaborative methods for prevention, detection, tracking, tracing, compliance and enforcement.

The FDA and Substandard, Falsified and Counterfeit Drugs

The FDA initially commissioned the IOM for the study. In a press release issued by the FDA, Margaret A. Hamburg commends the IOM on the report and for identifying strategies for addressing SFC medicines.

“The IOM report spotlights a critical global public health issue,” said Hamburg, FDA Commissioner. “Falsified and substandard medicines adversely affect the lives of millions around the world, and the issue must be elevated to the highest levels of international discourse.”

Hamburg also noted the FDA is focusing on a more global perspective concerning pharmaceutical safety and quality. Many of the actions recommended by the IOM are already in place at the FDA, she noted, including strengthening global regulatory capacity, advancing technology, strengthening surveillance, developing science-based standards and engaging in global dialogue.

The FDA currently maintains an overseas presence in 12 countries, in seven regions, and is actively involved with the World Health Organization (WHO) new member state mechanism. Additionally, the FDA participates in the Pacific Economic Cooperation (APEC) Regulatory Harmonization Steering Committee (RHSC) roadmap. This program aims to improve the quality and supply chain integrity of global pharmaceutical products.

“The FDA recognizes that all countries need to work together to ensure safe medicinal products for their citizens due to the increasing complexity of the global economy,” said Hamburg in the statement. “The FDA remains committed to engaging with multiple stakeholder groups to advance global solutions and minimize exposure of consumers to unsafe products.”


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.